Adial Pharmaceuticals, Inc.

NasdaqCM ADIL

Adial Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Adial Pharmaceuticals, Inc. Capital Expenditure is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Adial Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00.
Adial Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -64.61 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: ADIL

Adial Pharmaceuticals, Inc.

CEO	Mr. Cary John Claiborne MBA
IPO Date	July 27, 2018
Location	United States
Headquarters	1180 Seminole Trail
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Key trends

Past 5 years